Page Loading...
Layout Table~~~~2657~2657~~
The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023~
Published By VisionGain, June 2008

Visiongain have the pleasure of announcing the latest edition of their industry leading report - The World OTC Pharmaceutical Market, 2008-2023. This edition updates the world OTC market at present and predicts its sales revenues and trends from 2008-2023, including drivers and restraints on the market. Sources used include industrial databases, commercial and financial news, published reports and policy documents, interviews and questionnaires. Visiongain applied financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market-based report with detailed analysis and informed opinion. The report examines the worldwide OTC market, breaking down present and forecasted sales revenues into leading therapeutic categories and national markets. Visiongain also provides forecasts for leading OTC brands.~Published by VisionGain, June 2008

Visiongain have the pleasure of announcing the latest edition of their industry leading report - The World OTC Pharmaceutical Market, 2008-2023. This edition updates the world OTC market at present and predicts its sales revenues and trends from 2008-2023, including drivers and restraints on the market. Sources used include industrial databases, commercial and financial news, published reports and policy documents, interviews and questionnaires. Visiongain applied financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market-based report with detailed analysis and informed opinion. The report examines the worldwide OTC market, breaking down present and forecasted sales revenues into leading therapeutic categories and national markets. Visiongain also provides forecasts for leading OTC brands.

In particular, this report concentrates on the following essential aspects of the global OTC industry:Why you should buy this report:Visiongain forecasts that OTC pharmaceutical sales will almost double from 2007 levels by 2023. In the period 2008-2023, the worldwide OTC market will undergo a period of dynamic change. Increasingly aging populations and rising incidence of lifestyle diseases, as well as the need to reduce healthcare costs, will open up new therapeutic areas for OTC switching. Likewise, sales of existing OTC products will rise. At the same time, changes in retail patterns and new ways of advertising will open up access to OTC drugs to a public better educated and more interested in self-medication than at any previous time. Taking advantage of such opportunities will take considerable skill in a crowded and competitive marketplace. Consequently, the commercial prospects are very good for companies well placed to serve those growing needs. In these difficult times for the global pharmaceutical industry, OTC sales will become increasingly important, visiongain concludes.

Further unique benefits to you when you order this report:Sample Pages~The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023 (Single User License)|1186|The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023 (Departmental License)|1187|The World OTC Pharmaceutical Market Analysis & Forecasts, 2008-2023 (Company Wide License)|1188|~2657~3355~~
The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023~
Published by VisionGain, May 2008

The pharmaceutical industry is one of the fastest growing sectors in Indian economy. Visiongain predicts that market for pharmaceuticals in India has strong potential for increased growth from 2008 right through to 2023. The industry’s leading Indian Pharma report contains unique market-based research, including detailed interviews with key opinion leaders based in India and abroad. Importantly, the report forecasts the overall Indian pharmaceutical market from 2008 to 2023, as well as that of many important market segments. Other key metrics are also included throughout the report. This is your opportunity to gain critical insight into the potential and inner workings of one of the world’s most important healthcare markets from the present onwards.~Published by VisionGain, May 2008

The pharmaceutical industry is one of the fastest growing sectors in Indian economy. Visiongain predicts that market for pharmaceuticals in India has strong potential for increased growth from 2008 right through to 2023. The industry’s leading Indian Pharma report contains unique market-based research, including detailed interviews with key opinion leaders based in India and abroad. Importantly, the report forecasts the overall Indian pharmaceutical market from 2008 to 2023, as well as that of many important market segments. Other key metrics are also included throughout the report. This is your opportunity to gain critical insight into the potential and inner workings of one of the world’s most important healthcare markets from the present onwards.

This new visiongain report describes India’s domestic as well as export market for pharmaceuticals. India has had a strong domestic pharmaceutical industry and a rapidly expanding market with a population of over a billion and a rapidly expanding economy. Prevalence values of many diseases are likely to increase with expansion of population, urbanisation and with higher identification rates in the coming decade. India's pharmaceutical market is increasingly important in global pharma, with both domestic and foreign companies benefiting. Healthcare provision – both public and private – is improving, leading to fast-expanding markets for healthcare products, especially modern pharmaceuticals, visiongain concludes.

Outsourcing for Contract Research and Manufacturing Services from India

The report also analyses India’s role in pharma outsourcing services. India is emerging as a competitive outsourcing hub and is playing a major role in the global pharmaceutical industry in manufacturing Active Pharmaceutical Ingredients (APIs) and intermediates for drug makers. Global pharmaceutical companies are establishing long-term relationships with Indian manufacturing companies and contract research providers in India.

Generic drugs produced in India are increasingly being accepted worldwide, with leading companies such as Ranbaxy, Cipla and Dr. Reddy’s paving the way for others. Indian companies have increasingly taken on outsourced manufacturing for foreign clients, in addition to marketing pharmaceuticals themselves. There are also new drug development programmes by Indian companies, with eventual international market launches. Outsourcing to India has proven to be effective in saving costs and valuable developmental time. The Indian pharmaceutical industry has taken an important role in global pharma, not only as a manufacturer of generic drugs and APIs but also of new formulations.

Increasing costs for research and development and low productivity have compelled major pharmaceutical companies worldwide to outsource part of their research and manufacturing activities to lower-cost, developing nations such as India and China. India's emphasis on research and development and new drug discovery is growing. Furthermore, India is emerging as the preferred destination for outsourcing clinical trials, with both high quality and lower costs achieved there. Why You Should Buy This Report

In this report you will receive the following essential information for understanding the Indian pharma market and industry:This Report is essential reading for the Following Professionals, Amongst Others:Unique Benefits When You Order This Report:Great Potential for the Indian Pharma Sector and Market from Present Onwards, Visiongain Concludes
Currently, India's largest selling medicines are anti-infective agents, but the fast growing areas are the lifestyle-related diseases, the foreign multinational companies will benefit from selling innovative treatments for these conditions.

With increasing prevalence of diseases of aging and lifestyle-related diseases associated with greater affluence, India's pharmaceutical market will continue to increase steadily in sales value from 2008 onwards. Furthermore, with rapid increase in drug resistance for anti-infective agents like anti-TB, anti-malarial and other antibiotics, visiongain further emphasises that there will be a particularly strong market for most types of pharmaceutical agents – both new and established - from 2008 to 2023.

Sample Pages~The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023 (Single User License)|1194|The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023 (Departmental License)|1195|The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023 (Company Wide License)|1196|~2657~3362~~
Chinese Pharmaceutical Outlook 2008-2023~
Published by VisionGain, April 2008

This brand new report examines the prospects for the growth of pharmaceutical revenues in China. Visiongain predicts that total pharmaceutical revenues in China will increase from approximately $12bn in 2007 to over $30bn in 2013. This is a considerable increase, one that will represent a near tripling of total sales over six years. Strong growth will continue well beyond that period, as this report shows and explains.~Published by VisionGain, April 2008

This brand new report examines the prospects for the growth of pharmaceutical revenues in China. Visiongain predicts that total pharmaceutical revenues in China will increase from approximately $12bn in 2007 to over $30bn in 2013. This is a considerable increase, one that will represent a near tripling of total sales over six years. Strong growth will continue well beyond that period, as this report shows and explains.

Over 220 pages full of analysis, graphs, tables and charts – available to you today.

If you are interested in pharmaceutical business in China, you cannot afford to be without this report by visiongain’s leading authority on developing pharmaceutical markets. Visiongain’s Chinese Pharmaceutical Outlook 2008-2023 examines the exciting Chinese pharmaceutical market and industrial sector critically through comprehensive research and analysis. Visiongain applied techniques such as financial forecasting, surveying of key opinion leaders, SWOT analyses and discussion of qualitative factors. Societal, political, economic and commercial issues are covered. The result is a comprehensive market-based report with detailed analysis and informed opinion. This original 220+ page study contains 57 tables and 47 figures. We invite you to examine the table of contents included here.

In particular, visiongain’s Chinese Pharmaceutical Outlook 2008-2023 concentrates on the following themes:Why you should buy this report: The dominant pharmaceutical markets of North America, Western Europe and Japan currently account for over 80% of revenues for prescription drugs worldwide. However, there is great concern about the relatively low growth of those established markets in recent years. Consequently, international pharmaceutical companies are striving to raise their profiles in the developing markets of Asia, Latin America and Eastern/Central Europe. Principal amongst those developing markets is the emergent demographic and economic colossus of China.

Growth of the pharmaceutical markets in developing nations will clearly surpass that of the established markets throughout the foreseeable future. That situation will provide one of the greatest opportunities ever available to the international pharmaceutical industry. Those strongly growing national economies drive the reform and broadening of healthcare systems, with increasing sales in all healthcare sectors. Improvements in both the quality and reach of these healthcare provisions will drive the sales of branded and generic drugs in particular. This report will help you to understand those developments and opportunities.

Other benefits to you when you order this report:Sample Pages~Chinese Pharmaceutical Outlook 2008-2023 (Single User License)|1204|Chinese Pharmaceutical Outlook 2008-2023 (Departmental License)|1205|Chinese Pharmaceutical Outlook 2008-2023 (Company Wide License)|1206|~2657~3371~~
Lipitor Market analysis and forecasts Report, 2007-2012, 2017 & 2023~
Published by VisionGain, April 2008

In 2006, Pfizer’s Lipitor (atorvastatin) generated global revenues of $13.6bn, making it the best selling drug in pharmaceutical history. The blockbuster medicine has single-handedly driven the overall revenue margins of the cardiovascular segment, as this area continues to dominate the pharmaceutical market. Despite the maturing status of Lipitor, the drug has repeatedly maintained steady growth over the past 5 years, crowding out the yearly revenues of other lipid-regulating blockbuster drugs: Merck& Co’s Zocor and Zetia, Astrazeneca’s Crestor, Abbott’s Tricor and Bristol Myers Squibb’s Pravacol.~Published by VisionGain, April 2008

In 2006, Pfizer’s Lipitor (atorvastatin) generated global revenues of $13.6bn, making it the best selling drug in pharmaceutical history. The blockbuster medicine has single-handedly driven the overall revenue margins of the cardiovascular segment, as this area continues to dominate the pharmaceutical market. Despite the maturing status of Lipitor, the drug has repeatedly maintained steady growth over the past 5 years, crowding out the yearly revenues of other lipid-regulating blockbuster drugs: Merck& Co’s Zocor and Zetia, Astrazeneca’s Crestor, Abbott’s Tricor and Bristol Myers Squibb’s Pravacol.

However, as Lipitor’s blockbuster revenue is seriously threatened by imminent patent expiration in some of the drug’s largest markets such as the US, Japan and the UK, there is significant unrest between Pfizer’s key stakeholders about the future of the drug. Principally, amongst the heightened Lipitor topics are the imminent exposure of the $1 billion annual drug sales or more, as well as the fast expanding generic market in which India’s Ranbaxy is a dominant force.

What questions does the report answer? As Pfizer’s Lipitor struggles to fend off the immediate entry of Ranbaxy’s generic Lipitor, in key markets, the legal challenges surrounding the number one drug have set a new benchmark for pharmaceutical companies protecting branded products. Industry observers including Visiongain predicts that Pfizer’s crises are far from over, as the high revenue streams of Lipitor will experience significant challenges before the commencement of the next decade.

Moreover, Pfizer’s lack of success to replace Lipitor with Torcetrapib has escalated the company’s near-term battles besides the ever-tighter regulatory hurdles, reduced R&D efficiency and increased competition, creating formidable therapeutic challenges as healthcare payers influence pricing. Nevertheless, there are strong drivers of growth including unmet therapeutic needs, the rising incidence of multiple diseases, ageing populations, the rising living standards and fast-developing geographical markets. The future of Lipitor is therefore vitally important to Pfizer, especially in this uncertain period of economic changes and pressures.

This report includes detailed five-year forecasts over the period 2008-2013, and NOW features 10 and 15-year forecasts to help you understand the medium-term prospects for these markets.

Why You Must Buy This Report:

This unique in-depth management report examines the future prospects for Lipitor from 2008-2023. It delivers direct to you future sales forecasts for leading Lipitor in all seven major markets (7MM). This detailed report highlights the most compelling must know issues- Lipitor’s patent contention by Pfizer in both 7MM and other markets in order to block Ranbaxy’s immediate penetration of generic Lipitor. In light of healthcare drug bills increasing exponentially, generic Lipitor will be welcomed by managed care organisations (MCO) and further widen the generic revenue margins, visiongain concludes. This report also tackles Lipitor’s significant developments, potential opportunities on the market and important contemporary matters, especially commercial drivers and restraints.

Unique benefits to you when you order this report:Sample Pages~Lipitor Market analysis and forecasts Report, 2007-2012, 2017 & 2023 (Single User License)|1210|Lipitor Market analysis and forecasts Report, 2007-2012, 2017 & 2023 (Departmental License)|1211|Lipitor Market analysis and forecasts Report, 2007-2012, 2017 & 2023 (Company Wide License)|1212|~2657~3374~~
Blood Disorders Market Analysis & Forecasts Report to 2013~
Published by VisionGain, April 2008

In 2007, blood diseases cost the US’s economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. From oxygen delivery to immunological defence to clotting, blood has vital physiological functions, and clear, expensive treatments.~Published by VisionGain, April 2008

In 2007, blood diseases cost the US’s economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. From oxygen delivery to immunological defence to clotting, blood has vital physiological functions, and clear, expensive treatments. This brand new blood diseases treatments report breaks down therapies into four main groups:In 2006 visiongain valued this market at $37406m, But do you know how the blood diseases treatments market will fare 5, 10 and 15 years from now? Will it increase in sales and bring in significant profits or will it be rocked by widespread patent expiration and ensuing generic competition? This report provides these answers, with detailed quantitative and qualitative analysis. This is information every player in the blood diseases treatments market should not be without.

Visiongain’s new Blood Disorders 2008 report covers:This study was achieved through research of relevant news, company reports, expert opinion, academic literature and gold-standard IMS databases. Financial forecasting based upon in-depth research was performed, with accompanying SWOT analyses. The result is a comprehensive market-based study with extensive analysis and informed opinion.

Why You Should Buy This Report

This 115+ page report features over 25 tables, 50 graphs, market forecasts, current news, detailed insight, the latest developments, all with up-to-date analysis and informed opinion. This visiongain report is a vital aid to your gaining an understanding of this important market sector, giving your company 'the edge' on its competitors.

Importantly report gives answers to relevant questions such as:Other benefits to you when you order this report:Sample Pages~Blood Disorders Market Analysis & Forecasts Report to 2013 (Single User License)|1216|Blood Disorders Market Analysis & Forecasts Report to 2013 (Departmental License)|1217|Blood Disorders Market Analysis & Forecasts Report to 2013 (Company Wide License)|1218|~2657~3376~~
Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The challenge of turning technology into therapy~
Published by VisionGain, July 2007

Increasingly the large pharmaceutical companies are pumping money and ambition into the DNA/RNA therapy market. Whether its through forming collaboration/licensing agreements, or acquiring smaller companies they can see the financial opportunities. In particular the large pharmaceutical companies Pfizer, Sanofi-Aventis, Eli Lilly & Company and Merck & Co all have substantial investment in the RNA/DNA therapy products market. With Merck & Co in particularly showing its faith in the future potential of this market by taking the gamble of acquiring the specialist RNAi company Sirna, towards the end of 2006.~Published by VisionGain, July 2007

Increasingly the large pharmaceutical companies are pumping money and ambition into the DNA/RNA therapy market. Whether its through forming collaboration/licensing agreements, or acquiring smaller companies they can see the financial opportunities. In particular the large pharmaceutical companies Pfizer, Sanofi-Aventis, Eli Lilly & Company and Merck & Co all have substantial investment in the RNA/DNA therapy products market. With Merck & Co in particularly showing its faith in the future potential of this market by taking the gamble of acquiring the specialist RNAi company Sirna, towards the end of 2006.

This interest reflects the advances being made in this sector and implies that it is eventually on the verge of success. The investment of these larger companies makes that success both more likely to occur and more likely to occur quickly. Are you missing out? Have you positioned your company correctly to benefit from these opportunities? The vast potential of RNA/DNA therapies to treat the cause of disease across many therapeutic areas is set to be realized. Be part of that now.

This brand new high-level management report focuses on the commercial and strategic opportunities within the human genome project. It examines the companies utilizing novel molecular biological techniques to try to exploit this knowledge to produce RNA/DNA products. The genetic characterisation of many viruses is also leading to DNA and RNA products being used to treat infectious disease, a therapeutic area for which traditional drug development is difficult, as with the recent announcement regarding AIDS research.

Visiongain has identified 68 companies actively involved in this field, 35 of these companies are primarily focused on the development of RNA/DNA therapy products and 33 companies are involved in collaborations. This represents a substantial investment in the future of the RNA/DNA therapy products market and over the forecast period visiongain believes this investment will begin to pay off. There are 2 RNA/DNA therapy products due to submit licence applications in 2007, with a further 67 products in clinical trials and a further 45 products in pre-clinical development. Of these products visiongain has identified 14 that it believes have the greatest potential both to be launched before 2012 and to make a contribution to this market. This would result in a substantial increase in the RNA/DNA therapy product market over the forecast period and imply that this sector is eventually achieving some of its anticipated potential.

Why you must buy the RNA/DNA Therapy Products Market Forecasts report:

There are many companies using established and novel molecular biological techniques to try to produce successful RNA/DNA products for a variety of indications. However, even with substantial investment, the RNA/DNA therapy products market is still in its infancy, only three products have obtained a licence and only Macugen, for wet AMD, is actively available on the worldwide markets. RNA/DNA therapy products have faced problems, principally due to immunogenicity and in proving effective enough, primarily due to inefficient delivery systems.

This exclusive management report delivers:

In the short term the leading potential therapeutic area for RNA/DNA therapy products is ocular disease. Macugen, an aptamer for the treatment of wet AMD, is the only RNA/DNA product currently available worldwide. Visiongain predicts that Macugen will lead the RNA/DNA therapy products market between 2007 to 2012, generating in the region of $1.7bn in cumulative sales over this period. However, it is the cardiovascular sector, with 5 products predicted to launch before 2012, where visiongain anticipates RNA/DNA therapy products will ultimately have the greatest impact.

DNA therapy products is the sector that has the greatest investment, with the most specialist companies and the greatest number of products predicted to launch prior to 2012. However, antisense is the sector with the most collaborating companies and it also has the product Genasense, which has filed for an EU and US license, although it is encountering problems in obtaining these licenses and its future is by no means certain.

RNAi technology undoubtedly has huge potential for developing products in many therapeutic areas. The investment in novel, often nanoparticle, delivery systems for RNAi products may ensure that this potential is ultimately realised. If solutions for efficient delivery of RNAi can be solved early on in RNAi development the RNA/DNA therapy market may see a future expansion due to successful RNAi therapies. RNAi has the potential to emerge as a dominant section of the RNA/DNA therapy products market, but only time will tell if it can ultimately fulfil this potential.

Over the forecast period 2007-2012 RNA therapy products are not likely to generate substantial sales.

Unique benefits to you when you order this report:

Chapter 1. Executive Summary

Chapter 2. Introduction to RNA and DNA products

2.1.The biology of DNA, RNA, transcription and translation
2.1.1. DNA and RNA
2.1.2. Translation
2.1.3. Transcription
2.2. The genetic basis of disease
2.2.1. The genetic basis of inherited diseases
2.2.2.The genetic basis of cancer
2.2.3.The genetic basis of immune and autoimmune disease
2.3. The use of RNA and DNA products to silence genes
2.3.1. DNA gene therapy
2.3.2. Antisense
2.3.3. Interfering RNA
2.3.4. Chimera based gene therapy
2.3.3. Aptamers
2.3.6. Ribozymes and DNAzymes
2.3.7.DNA Vaccines
2.4. Mode of delivery of DNA and RNA therapy
2.4.1. Viral vectors
2.4.2. Non-viral vectors
2.5. A brief history of gene therapy
2.5.1. Gene therapy in infectious disease
2.5.2. Gene therapy in inherited disease
2.5.3. Gene therapy in cancer
2.5.4. Gene therapy in immune and autoimmune disease
2.6. Summary

Chapter 3. Top companies and products in the Aptamers market 2007-2012

3.1. Leading companies and products in the aptamer market
3.1.1. OSI Pharmaceuticals and the continuing story of the ownership of Macugen
3.1.2. Archemix hold the keys to therapeutic aptamer development
3.1.3. SomaLogic Inc. and diagnostic aptamers
3.1.4. Spiegelmers, second generation aptamers developed by NOXXON Pharma
3.1.5.Nuvelo are developing anticoagulant aptamers with Archemix
3.1.6. Aptamera is acquired by Antisoma
3.1.7. Regado Biosciences are developing antidote controlled anticoagulants
3.2. Summary of the top 5 aptamer companies, Archemix leads the way
3.3. Summary of the leading developmental aptamer products and their potential markets
3.4. Macugen, the leading aptamer product
3.4.1. Age-related macular degeneration
3.4.2.Macugen- effectiveness, current licenses and future applications
3.4.3. The ocular disease market 2006
3.4.4. Future competitors in the AMD market, Evizon and Bevsiranib due to start phase III trials
3.4.5. Comparison of the leading AMD therapies, Lucentis is the market leader
3.4.6. The AMD market 2007-2012 and revenue forecast for Macugen
3.5. Summary

Chapter 4. Top companies and products in the antisense market 2007-2012

4.1. Phase III failures in antisense
4.2. Key companies and products in the antisense market
4.2.1. Vitravene, the first antisense product to obtain a license
4.2.2. Isis Pharmaceuticals is the leading antisense company
4.2.2.1. Isis’s development and licensee partners
4.2.2.2. Isis’s strong antisense pipeline
4.2.2.3. Alicaforsen, Isis’s leading product
4.2.2.4. Isis’s cholesterol lowering, cancer, diabetes and multiple sclerosis antisense products in phase II trials
4.2.2.5. Isis’s pre-clinical product ISIS 369645 for asthma
4.2.3. Is Genasense on the verge of success or failure?
4.2.4. AVI BioPharma plan to launch Resten-CP for retenosis within 5 years
4.2.4.1. AVI BioPharma and Ercole Biotech are collaborating on developing splice-altering technologies
4.2.4.2. AVI BioPharma have collaborations with Eleos and the Defence Threat Reduction Agency
4.2.5. OncoGenex and antisense drugs to reduce cancer drug resistance
4.2.6. Antisense Therapeutics are developing antisense for autoimmune disease
4.2.7. Ester Neurosciences and antisense for neurological disorders
4.2.8. Santaris Pharma and RNA antagonists
4.2.9. Lorus Therapeutics and GTI-2040 for cancer
4.2.10 Enzo Biochem and HGTV43, anti-HIV antisense
4.2.11. Isis is the leading antisense company, who else is in the top 5?
4.3. The antisense market 2007-2012, products likely to succeed
4.3.1. The potential market for Genasense is not substantial
4.3.2. Alicaforsen could take a share of the $800m UC market
4.3.3. The considerable potential of the Resten family of antisense products
4.3.4. ISIS 301012 could enhance the effects of statins
4.4. Summary

Chapter 5. Top companies and products in the DNA therapy products market 2007-2012
5.1. Gendicine is licensed in China
5.2. Key companies and products in the DNA therapy product market
5.2.1.Introgen’s large gene therapy product pipeline
5.2.1.2. NGN 241 for head and neck cancer
5.2.1.1. Introgen’s lead product Advexin could be launched in 2008
5.2.1.3.INGN 234, a novel product for prevention of oral cancer and the cancer vaccine INGN 234, are in phase II trials
5.2.1.4. Introgen’s early stage products
5.2.2. Cardium therapeutics and Generx for recurrent angina
5.2.3 Gencell Aventis have NVIFGF in phase III trials
5.2.4. GenVec and TNFerade for pancreatic cancer
5.2.5. AnGes is developing cardiovascular and autoimmune gene therapies
5.2.6. VIRxSYS is producing a lentivector for HIV treatment
5.2.7. Applied Genetic Technologies Corporation hope to launch AGTC-0106 in 2009
5.2.8. Amsterdam Molecular Therapeutics is developing gene therapy for metabolic and ocular disease
5.2.9. Epeius Biotechnologies are developing Rexin- G and other targeted gene therapy products
5.2.10. Asklêpios Biopharmaceuticals Inc anticipates the launch of Biostrophin in 2010
5.2.11.Neurologix and NLX-E201 for Parkinson’s disease
5.2.13. Oxford BioMedica hope to register TroVax in 2009
5.2.14. Vical, has patented plasmid DNA delivery technology
5.2.14.1. Vical has Allovectin-7 in phase III trials
5.2.15. Transgene
5.2.15.1. Roche obtain worldwide license for TG 4001 cervical cancer vaccine
5.2.15.2. TG 4010, TG 1042 and MyoSys are in development
5.2.16. Coley and CpG oligonucleotides
5.2.17. Bavarian Nordic is branching out into therapeutic vaccines
5.2.18. Virax and VIR201 HIV DNA vaccine
5.3. Who are the top 5 companies in the DNA therapy products market?
5.4. The DNA therapy products market 2007- 2012
5.4.1. Ten DNA therapy products could potentially be launched by 2012
5.4.2. Cancer is the leading indication for DNA therapy products likely to launch prior to 2012
5.4.3. The immediate potential market for Advexin is not substantial
5.4.4. Generex and NVIFGF could become leading products in the cardiovascular and RNA/DNA therapy market
5.4.5. Can the cancer vaccines, TroVax, Allovectin-7, PF-351267 and TG4001 make their mark on the cancer therapies market?
5.4.6. Biostrophin or AGTC-0106 could be the first gene therapy products for inherited disease
5.4.7. INGN 234, a product to watch
5.5. Summary of the DNA therapy products market 2007-2012

Chapter 6. Top companies and products in the RNA therapy products market 2007-2012
6.1. Where is the RZ market in 2007?
6.2. The promise of RNAi
6.3. Key companies and products in the RNA therapies market
6.3.1. Sirna acquired by Merck & Co
6.3.2. The newly formed company Opko Corporation, has the leading RNAi product Bevasiranib
6.3.3. Gene Shears’s hammerhead RZ for HIV
6.3.4. Alnylam Pharmaceuticals hold patents on RNAi technology
6.3.5. CytRx subsidiary RXi is dedicated to the development of RNAi products
6.3.6. Silence Therapeutics and RTP801i for AMD
6.3.7. Intradigm Corporation and ICS-283 cancer therapy
6.3.8. Nucleonics Inc. and NUC B100 for hepatitis B infection
6.3.9. Nastech Pharmaceutical Company is developing inhaled RNAi products
6.3.10. Calando Pharmaceuticals and RONDEL
6.3.11. The antisense company Lorus Therapeutics is also developing an RNAi product
6.3.12. Who is the leading RNA therapy product company?
6.4. The RNA therapy market 2007-2012
6.4.1. The potential market for Bevasiranib
6.4.2. The potential market for HIV hammerhead RZ therapy
6.4.3. Infectious disease is the most promising potential market for RNA therapy products
6.5. Summary and outlook for the RNA therapy products market

Chapter 7. Issues affecting the RNA/DNA therapy products market

7.1. Principle drivers of the RNA/DNA therapy market
7.2. Principle restraints on the RNA/DNA therapy market
7.3. Summary

Chapter 8. Conclusion

8.1. The top 20 companies in the RNA/DNA therapy products market
8.2. Summary of the RNA/DNA therapy market 2007-2012
8.2.1. Macugen is the leading RNA/DNA therapy product
8.2.2.Genasense and Advexin are due to submit license applications in 2007
8.2.3. The RNA/DNA therapy products pipeline is sizeable
8.2.4 Fourteen RNA/DNA therapy products could potentially be launched prior to 2012
8.2.5. Cancer is the leading indication for the development of RNA/DNA therapy products
8.2.6. Cardiovascular disease is the sector that may ultimately gain the most from RNA/DNA therapy products
8.3. Summary

Sample Pages~Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts (Single User)|1104|Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts (Departmental)|1105|Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts (Company Wide)|1106|~2657~3294~~
Anti-Obesity Treatments 2007-2012 – A blockbuster target market~
Published by Visiongain, July 2007

This high-level management report examines the commercial prospects for anti-obesity prescription drugs in the global healthcare market. With obesity now the most common nutritional disorder in western industrialised countries, is your company’s pipeline showing the potential blockbuster the market offers? Obesity in the US and Europe has already reached high levels, with obesity being described as an epidemic and a “public health time-bomb”. Government funding continues to increase, especially in the most seriously affected areas – the US and Europe.~Published by Visiongain, July 2007

“By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, researcher has found”. For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities.

This high-level management report examines the commercial prospects for anti-obesity prescription drugs in the global healthcare market. With obesity now the most common nutritional disorder in western industrialised countries, is your company’s pipeline showing the potential blockbuster the market offers? Obesity in the US and Europe has already reached high levels, with obesity being described as an epidemic and a “public health time-bomb”. Government funding continues to increase, especially in the most seriously affected areas – the US and Europe.

The U.S. health panel's rejection of Sanofi-Aventis' obesity drug Zimulti however has cast a shadow over other experimental products in the same class while offering a stark reminder of challenges facing the development of weight-loss medications. The Food and Drug Administration advisory panel on Wednesday unanimously recommended Zimulti not be approved because of concerns it may increase suicidal thinking and depression. The FDA is expected to make a final decision by July 26.

Obesity is an major risk factor for serious, chronic diseases such as type 2 diabetes, heart disease, stroke and certain cancers. In addition, obese people are more likely to suffer from psychological problems and a poorer quality of life in general. The increase in obesity during recent decades involves a complex interplay of environmental, social, economic, genetic and behavioural factors. Its most prominent causes include unhealthy modern diets – high in sugars and fats - and reduced physical activity.

New drugs in the field have the potential to treat a range of conditions associated with metabolic syndrome, with high potential revenues and life cycle benefits. Visiongain concludes that the commercial opportunities for anti-obesity medications are significant, predicting multi-billion revenues for the anti-obesity segment by early next decade. Nevertheless, there are many hurdles that market participants will have to overcome, particularly convincing healthcare authorities and practitioners that the drugs have adequate efficacy, safety and cost-effectiveness.

Anti-Obesity Treatments 2007-2012, examines the market for anti-obesity drugs critically, through comprehensive primary and secondary research. In addition to consultation with experts in medical practice, academia and industry, this research involved a detailed study of policy documents, industrial reports and relevant news. Importantly, visiongain also applied techniques such as financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based report with detailed analysis and informed opinion.

In particular, Anti-Obesity Treatments 2007-2012 concentrates on the following essential aspects of the market:

Why you should buy this report:

The market for anti-obesity drugs has proved far more difficult to conquer than most companies expected. In 2006, that market segment generated sales of over $1300m worldwide. There have been problems in marketing products, with concerns over safety and efficacy having a negative impact on sales. There have been major disappointments, but important commercial opportunities remain.

Visiongain predicts that the anti-obesity market will exhibit strong growth in revenues from 2007-2012, with significant investments being made by far-sighted companies in the pharmaceutical industry. Although sales have been only modest so far, anti-obesity drugs will increasingly gain acceptance from stakeholders in healthcare. High revenues should then be possible over the coming years, with at least one blockbuster product emerging by 2012.

The period 2007-2012 is a very exciting and decisive period in the development of anti-obesity drugs. Some experts predict that anti-obesity drugs will eventually work as reliably as anti-hypertensives and lipid regulators. There are significant opportunities for companies in providing safe and effective drugs that help patients with short- and long-term weight loss/management. Far-sighted companies are already investing in the high potential of the anti-obesity market.

Clearly, obesity is going to remain a leading health problem for decades to come. It is inevitable, however, that progress will be made in treating that often-recalcitrant condition. There lies one of the most important challenges for the pharmaceutical industry, in conjunction with healthcare authorities, since the lives of millions depend upon progress in treatments.

Table of Contents

1 Executive Summary: Anti-Obesity Treatments 2007-2012

2 An Introduction to Obesity and Its Treatment

2.1 What is Obesity?
2.1.1 How Serious is the Problem?
2.1.2 Fat is Necessary to Store Energy in the Body
2.1.3 Drugs Have a Role in Treating Obesity
2.1.4 Obesity is a Chronic Disease
2.1.5 Obesity Greatly Increases Risk Factors for a Range of Other Diseases
2.1.6 Obesity is Very Prevalent Worldwide
2.1.7 Body Weight is Dependent Upon Several Factors
2.2 How is Obesity Measured?
2.2.1 Weight-for-Height Tables
2.2.2 Body Mass Index
2.2.3 Waist Circumference
2.3 Urbanisation, Modernisation and Economic Development Have Contributed to Obesity
2.3.1 Urban Areas Show Higher Levels of Obesity
2.3.2 Technological Developments Have Contributed to the Problem of Obesity
2.3.3 Modernisation Has Effected Obesity Levels in Native Populations
2.4 Those Most At Risk Are Poor in Developed Countries and Wealthy in Developing Nations
2.4.1 Importing Poor Eating Habits
2.4.2 The Costs of Poor Diets to Individuals and Society
2.5 Obesity Overtakes Smoking for Medical Costs in the US
2.6 Obesity in the US
2.6.1 Prevalence of Obesity Has Increased Steadily in Recent Years
2.6.2 There is a High Prevalence of Obesity Among Children in the US
2.7 Obesity in the UK
2.7.1 High Incidence and Social Costs
2.7.2 Increasing Juvenile Obesity
2.7.3 National and Local Efforts Required
2.8 Effects of Obesity on Health: Linked Conditions Have High Social and Economic Cost
2.9 Childhood Obesity
2.10 Factors Causing Obesity
2.10.1 Genetics
2.10.2 Specific Genetic Factors
2.10.3 Environment
2.10.4 Diet
2.10.5 Behaviour
2.10.6 Regular Physical Exercise
2.11 Treatment of Obesity
2.12 Treatment of Obesity With Drugs
2.12.1 Drugs May be Used Under Strict Clinical Guidance
2.12.2 Types of Drugs for Treating Obesity
2.13 Lipase inhibitors
2.13.1 Orlistat the First of the Lipase Inhibitors Currently Leads the Anti-Obesity Market
2.14 Anorectic Drugs
2.14.1 Sibutramine Has Achieved Modest Success
2.14.2 Phentermine Hydrochloride – An Older Drug
2.14.3 Rimonabant – a Promising Cannabinoid Receptor Blocker
2.15 There is Much Scope for Future Development of Treatments for Obesity

3 The World Market for Anti-Obesity Drugs, 2006-2012

3.1 The Anti Obesity Market Generated Sales in Excess of $1bn in 2006
3.1.1 Xenical and Meridia Overcame Difficulties in the Anti-Obesity Market in the Late 1990s
3.1.2 New Drugs Such as Acomplia Have High Expectations to Live Up To
3.1.3 Reductil/Ectiva/Meridia and Xenical Have More Limited Scope for Expanded Indications than Acomplia
3.2 Xenical and Reductil/Ectiva/Meridia are More Limited in their Scope for Gaining Further Indications than Acomplia
3.3 The Anti-Obesity Market Has Proved Very Difficult to Crack So Far
3.3.1 Only Two Drugs are Currently Approved for Long-Term Treatment of Obesity
3.3.2 Visiongain Believes That Significant Advances Will Occur in this Market With Potentially High Revenues for Next-Generation Products
3.4 Roche Currently Leads the Global Prescription Anti-Obesity Market
3.5 The Global Anti-Obesity Market Will Expand Strongly from 2006 to 2012
3.5.1 Xenical and Reductil will be Overtaken by Acomplia
3.5.2 Life-Long Therapy with Drugs May Constitute the Future of Obesity Management
3.6 Xenical Will Continue to Show Growth to 2009 Then Decline Gradually
3.6.1 Xenical Versus Meridia – Efficacy and Side Effects
3.6.2 Completion of Key Studies on Orlistat in 2002
3.6.3 Indication for Use in Adolescents in both US and EU – a Significant Advantage for Xenical
3.6.4 US Label Change to Include Delay of Diabetes Type 2 Onset Information
3.6.5 Lifecycle Management Potential Includes Possible Anti-Cancer Role for Xenical
3.6.6 OTC Version of Orlistat Approved in the US – Licensing Deal With GSK
3.6.7 Discontinuation of Development of Orlistat by Chugai in Japan
3.7 Reductil/Ectiva/Meridia Will Also Lose Out to Acomplia from 2006-2012
3.7.1 Sibutramine is a Dual Serotonin (5HT)/Noradrenaline Re-uptake Inhibitor Launched in the US in 1998
3.7.2 Problems for Reductil/Meridia
3.7.3 Abbott has Entered into Various Licensing Deals for Sibutramine
3.8 Sales of Clobenzorex Will Continue to Expand Throughout the Forecast Period
3.9 Acomplia Will Be the First Blockbuster in the Anti-Obesity Market Segment Comment
3.9.1 Acomplia Launched in Europe in Mid 2006 with US Approval Pending
3.9.2 Acomplia Has Therapeutic Promise that Should Ensure High Sales
3.9.3 Acomplia Was Rejected by FDA Panel in June 2007 – Sanofi-Aventis Responded by Withdrawing its Application Temporarily
3.9.4 Success of Acomplia Will be Driven by Expansion of Indications
3.9.5 Phase III Results for Acomplia were Promising
3.9.6 Further Trials are in Progress for Acomplia
3.9.7 The RIO Studies on Diabetes and Lipids Were Promising for Acomplia
3.9.8 The SERENADE Trial Reinforced Earlier Studies – Amelioration of Other Aspects of Metabolic Syndrome
3.9.9 In Wake of FDA Panel Rejecting Acomplia, Sanofi-Aventis Announced Plans to Submit Additional Safety Data to European Authorities 3.9.10 Reimbursement for Acomplia is a Serious Concern for Sanofi-Aventis
3.9.11 Rights for Japan Reverting to Sanofi-Aventis 3.10 Sales of Phentermine Will Continue to Decline Slowly from 2006-2012
3.10.1 Phentermine is a Sympathomimetic Appetite Suppressant
3.10.2 Phentermine is a Long-Established Treatment that Still Achieves High Prescription Volumes – Generics Make it a Lower Cost Therapy
3.10.3 Phentermine Is Subject to the Controlled Substances Act in the US
3.11 Other Anti-Obesity Drugs Will Seize an Increasingly Significant Proportion of Total Sales in the Sector
3.11.1 There are Promising Developments Currently in Mid to Late Stage Clinical Testing
3.11.2 Compounds For Developed for Type 2 Diabetes Have Potential in Treating Obesity As Well
3.12 While the Past Has Been Difficult for Anti-Obesity Treatments, There is Optimism for the Future
3.13 The Anti-Obesity Market is Fragmented but Future Growth Is Assured by Rising Awareness of Obesity as a Major Health Problem in the Developed and Developing World
3.14 Safety Issues Affect Leading Anti-Obesity Drugs
3.15 The Anti-Obesity Market Will Expand Rapidly as Prescribers and Healthcare Providers Recognise the Pressing Need to Avert This Most Serious Threat to Health

4 Forces Affecting the Anti-Obesity Market

4.1 SWOT Analysis of the Anti-Obesity Market
4.2 An Expanding Patient Population Constitutes the Principal Driver in the Anti-Obesity Market
4.3 The Principal Restraints in the Anti-Obesity Market
4.4 Major Success in the Anti-Obesity Drugs Market Has Proved to Be Elusive to Date
4.4.1 Many Doctors and Healthcare Bodies Believe that Drugs Play an Important Role in Treating Obesity
4.5 Safety Concerns Over Anti-Obesity Treatments
4.5.1 Market for Anti-Obesity Drugs Has Encountered Mixed Fortunes in Recent Years
4.5.2 Two Drugs Approved for Long-Term Treatment of Obesity
4.5.3 The Anti-Obesity Market Suffered After the Withdrawal of Fenfluramine and Dexfenfluramine
4.5.4 Public Citizen Filed a Petition With The FDA Claiming that Xenical Should be Withdrawn
4.5.5 Obstacles facing US Approval for Rimonabant Casts Shadow Over Other Obesity Drugs
4.6 The World Health Organisation Considers Obesity to be an Epidemic
4.7 Convincing Stakeholders of the Efficacy and Safety of Anti-Obesity Drugs Remains a Great Challenge for the Industry
4.7.1 There is a Persisting Belief That Drugs Have a Limited Role in Treating Obesity
4.7.2 Lack of Adequate Reimbursement Limits Potential of Anti-Obesity Drugs
4.8 US Health Gains Weakened by High Incidence of Excessive Weight and Obesity
4.8.1 Overweight and Obesity Are Among The Most Pressing New Health Challenges
4.8.2 Risks Caused by Obesity Compared with Those of Tobacco Use
4.8.3 Over Half of US Residents are Overweight
4.8.4 Community-Based Recommendations for Tacking Obesity in the US
4.9 EU Health Commissioner Reports That More Than Half Of Adults in the EU are Currently Overweight 4.10 Non Medicinal Treatments that Accompany Drug-Based Therapy – When Successful These Approaches Lessen the Requirement for Pharmaceuticals
4.10.1 Reducing Energy Intake Through Changes to Diet and Eating Patterns
4.10.2 Increasing Physical Activity
4.10.3 Behavioural Therapy
4.11 Weight Loss Surgery For Severe Obesity – A Last Resort When Drug-Based Treatments Fail
4.12 Potential Risks of Anti-Obesity Medication Other Than Side-Effects
4.12.1 Potential for Abuse or Dependence
4.12.2 Development of Tolerance
4.12.3 Reluctance to View Obesity as a Chronic Disease
4.13 Over-the-Counter Drugs and Herbal Remedies
4.13.1 OTC Version of Orlistat Approved in Early 2007
4.14 Obesity Will Constitute a Devastating Burden on Healthcare and on Society in General Unless it is Effectively Prevented and Treated
4.15 Critics Warn of Over-Reliance on Anti-Obesity Drugs
4.15.1 Use of Obesity Drug Increases in Britain
4.15.2 Critics Accuse Doctors of Overlooking Side Effects of Drugs and Healthcare Authorities of Not Doing Enough to Encourage Lifestyle Changes
4.15.3 Claims for Anti-Obesity Drug Disputed
4.16 Surgery And Drugs for Children To Tackle Obesity “Epidemic” in UK
4.17 There is Good Scope for New Drugs to Treat Obesity, Leading UK Expert Acknowledges
4.18 Controversy Over Vested Interests and Misinformation in Obesity

5 Obesity in the Leading Pharmaceutical Markets

5.1 The US Will Still Have The Highest Prevalence of Obesity in 2012
5.1.1 WHO Considers Obesity to be a Global Epidemic
5.1.2 Both Germany and the UK Will Have High Prevalence of Obesity
5.1.3 Lifestyle Issues Raising the Obesity Levels
5.2 Sales of Anti-Obesity Drugs Will Rise Steadily in the US from 2006 to 2012
5.2.1 The UK Will Have The Second-Highest Sales of Anti-Obesity Drugs
5.2.2 Although Japan Will Retain a Low Prevalence of Obesity, the Relative Increase in Numbers of Obese People Will Be High
5.3 High Cost of Obesity in the UK Will Drive Sales of Anti-Obesity Medication
5.4 Health Survey for England Shows Marked Increase in Childhood Obesity
5.5 Drive to Reduce UK’s High Obesity Levels Given Boost by Online Resource
5.6 The National Institutes of Health Recognise that Obesity Now Constitutes an Epidemic in the US
5.6.1 The NIH Obesity Research Task Force
5.6.2 Efforts in the US and Europe Will Benefit the Development of New Pharmaceutical Treatments for Obesity

6 Experts’ Views on Main Issues in the Treatment of Obesity

6.1 The Most Important Unmet Medical Needs in The Treatment of Obesity
6.2 The Most Favoured Type of Anti-Obesity Treatment by the Start of Next Decade
6.3 Future Prospects for Efficacy and Safety
6.4 Funding of Anti-Obesity Treatments
6.5 The Anti-Obesity Market in Developing Nations
6.6 Concluding Thoughts

7 Pipeline Developments in Anti-Obesity Treatments

7.1 Agents in Phase 2 of Clinical Development for Obesity
7.1.1 Novo Nordisk’s Liraglutide
7.1.2 Sanofi-Aventis’ Surinabant (SR 147778)
7.1.3 Pfizer’s CP 741952 and CP 866087
7.1.4 Alizyme’s Cetilistat (ATL 962)
7.1.5 Solvay’s SLV 319 (BMS 646256)
7.1.6 Amylin’s Pramlintide (Symlin, Normylin)
7.1.7 Kissei’s 869682
7.1.8 Metabolic’s AOD 9604
7.1.9 Sanofi-Aventis’ AVE 1625
7.1.10 Orexigen’s Bupropion/Zonisamide (Empatic/Excalia)
7.1.11 Genzyme’s GT 389255
7.1.12 Amgen’s Metreleptin
7.1.13 VIVUS’ Phentermine/topiramate (MK 0493)
7.1.14 7TM Pharma’s TM 30338
7.1.15 Shionogi’s S 2367
7.2 Agents in Phase 3 of Clinical Development for Obesity
7.2.1 Merck & Co’s Taranabant
7.2.2 Pfizer’s CP 945598
7.2.3 Orexigen’s Bupropion and Naltrexone (Contrave)
7.2.4 Arena’s Lorcaserin
7.3 Discussion of Current Pipeline Developments

8 Conclusions

8.1 Obesity is a Serious Condition With High Prevalence
8.2 Drugs Have a Role in Treating Obesity
8.3 The Anti-Obesity Market Has Proved Very Difficult to Crack So Far
8.4 The Global Anti-Obesity Market Will Expand Strongly from 2006 to 2012
8.4.1 Xenical and Reductil will be Overtaken by Acomplia
8.5 An Expanding Patient Population Constitutes the Principal Driver in the Anti-Obesity Market
8.6 The Principal Restraints in the Anti-Obesity Market
8.7 Geographical Breakdown of Revenues in the Anti-Obesity Market
8.7.1 The US Will Still Have The Highest Prevalence of Obesity in 2012
8.7.2 Both Germany and the UK Will Have High Prevalence of Obesity
8.7.3 Sales of Anti-Obesity Drugs Will Rise Steadily in the US from 2006 to 2012
8.7.4 The UK Will Have The Second-Highest Sales of Anti-Obesity Drugs
8.8 There are Promising Developments Currently in Mid to Late Stage Clinical Testing
8.9 Outlook for the Future

Sample Pages~Anti-Obesity Treatments 2007-2012 - A blockbuster target market (Single user)|1101|Anti-Obesity Treatments 2007-2012 - A blockbuster target market (Departmental)|1102|Anti-Obesity Treatments 2007-2012 - A blockbuster target market (Company Wide)|1103|~2657~3292~~
Global Smoking Cessation Market Analysis & Forecasts - Preparing for the first blockbuster~
Published by VisionGain, July 2007

Cigarette smoking is the most important source of preventable and premature morbidity worldwide. Currently, the number of smokers across the globe is estimated at 1.3 billion. Political moves are leading to national bans of smoking in public places, with the long-term aim to reduce the cost to the health sector. But what will be the short-term spending on smoking cessation therapies?~Published by VisionGain, July 2007

Cigarette smoking is the most important source of preventable and premature morbidity worldwide. Currently, the number of smokers across the globe is estimated at 1.3 billion. Political moves are leading to national bans of smoking in public places, with the long-term aim to reduce the cost to the health sector. But what will be the short-term spending on smoking cessation therapies?

In 2007 visiongain believes the anti-smoking market to be worth $1.7 billion. This is a growth of 37% from the year before. This latest report from visiongain, Global Smoking Cessation Market Analysis & Forecasts - preparing for the first blockbuster, explains just how this market will experience growth over the medium term future. Also do you know what the drivers and restraints of the market are? This report not only reveals these, but also details what strategies can be used to maximize profits from the drivers and restraints.

The report examines key smoking cessation markets such as:

In this report each one of these disease areas is examined in terms of market growth and revenue. Plus we examine how current and new drug treatments will take hold in each market, plus which companies will succeed in each market.

According to the findings of this new report, visiongain reveals that the nicotine vaccine market will generate over $1 billion plus that Pfizer's nicotinic receptor will be the markets first blockbuster drug.

Can any of these drugs compete with the OTC market leaders? How will GSK's Zyban be effected with direct competition from Chantix/ Champix? However are there any others which can compete with this for market share or beat its dominance? This report answers that question, with an analysis of other players in the market.

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC smoking cessation drugs by product type. The study also assess' the challenges faced by anti-smoking companies, and what exciting market opportunities exist in this up- and-coming therapeutic area.

Why You Must Buy This Report?

This report features tables, graphs and charts, news, insights, the latest developments and an in depth survey of the anti-smoking market with up-to-date analysis. This report is a vital addition to gaining an understanding of this profitable market sector and will give your company 'the edge' on your competitors. You can not afford to be without this latest report from visiongain.

With unmet medical needs this market and a growing user base, by how much will the market grow? Enough for some products to begin to lose revenue? This report will tell you. Brought together in one easy to read, easily digested format, this report will keep you fully informed and up-to-date on the global ophthalmic pharmaceutical market.

Key questions that this report answers are:Unique benefits to you when you order this report

Table of Contents

1. Executive Summary

2. Introduction

2.1 Smoking – Currently 1.3 Billion Smokers Worldwide
2.2 Second-hand smoke/Passive smoking Causes Lung Cancer
2.3 Medical Research in Smoking Related Problems
2.3.1 Effects of Smoking in Lung Cancer the Most Lethal of all Cancers Worldwide
2.3.2 Effects of Smoking in Emphysema
2.3.3 Effects of Smoking in Heart Disease
2.4 Cigarette Smoking Signs and Symptoms
2.5 Scope of the Report
2.6 Aims and Objectives

3. Social, Political and Economic effects

3.1 Current Policy & Expansion of Smoking Bans
3.1.1 Effects of Smoking Bans on Health
3.1.2 Financial Effects of Smoking Bans on Businesses
3.1.3 Outdoor Smoking Bans
3.1.4 Concerns over Smoking Bans
3.2 Can Complete Smoking Cessation Increase Healthcare Costs?
3.3 Anti-Smoking Organizations and Their Lobby
3.3.1 Establishing a Campaign to Assist Fighting Tobacco Addiction
3.4 Tobacco Prices: A Key Strategy in Reducing Smokers
3.5 Using Anti-Smoking Operations as a Health Promotion Campaign
3.6 Economic Impact on the Tobacco Industry
3.7 New Anti-Counterfeit Technology to Reduce Cigarette Smuggling

4. Can Drugs Deal With Addiction & Nicotine?

4.1 Overcoming the Psychological Dependence that is Addiction
4.1.1 Fighting the Psychological Addiction
4.1.2 What Areas to Target in the Fight against Physiological Addiction
4.1.3 Regulatory Control of Addiction
4.2 What the Pharma Industry is up against if Nicotine is the Hardest Addiction to Break
4.2.1 The Effects of Nicotine
4.2.2 Effects of Nicotine in the Brain
4.2.3 Combating the Effects of Nicotine in the Body
4.2.4 The Symptoms of Nicotine Toxicity
4.2.5 How to Assess the Level of Nicotine Addiction?

5. Treatment Overview

5.1 Smoking Cessation Aids
5.2 Nicotine Replacement Therapy (NRT)
5.2.1 Can Any Product Compete with a OTC Nicotine Gum
5.2.1.1 Nicorette - The Leading NRT Smoking Cessation Product
5.2.2 A More Rapid Effect through Nicotine Inhalers
5.2.3 Specific Quantities Through Nicotine Patches
5.2.4 Options Available in Nicotine Lozenge
5.2.5 Overcoming Sudden Craving Through Nicotine Nasal Spray
5.2.6 NRT Drug Summary and Sales
5.3 The Antidepressant Approach: Bupropion (Zyban)
5.3.1 However Zyban’s Revenue is Decreasing
5.4 Market Capturing by Varenicline (Chantix/ Champix)
5.4.1 Chantix/Champix Set to Become a Future Blockbuster?
5.5 Other Smoking Cessation Methods
5.5.1 Behaviour Modification Therapy
5.5.2 Cold Turkey
5.5.3 Hypnosis
5.5.4 Acupuncture

6. Pipeline

6.1 Anti-Smoking Market will be in High Demand
6.2 Effective Agents in Pre-Clinical Stage
6.2.1 Benztropine analogues
6.3 Agents in Phase I
6.3.1 EVT 302
6.3.2 400 Patient European Study of TA-NIC Could Lead to Exciting New Drug
6.4 Agents in Phase II
6.4.1 GSK’s 468816 May Still Have Hope
6.4.2 ADX 10061 Initiates Proof-of-Concept Study in the U.S
6.4.3 Surinabant (SR147778)
6.4.4 The Move of Selegiline to Combat Smoking
6.4.5 NicVax Meets Phase IIb Primary Endpoint Targets
6.4.6 NicQb to Utilise Immunodrug Technology
6.4.7 Somaxon’s Nalmefene Shows Successful Signs in Phase II
6.5 Sanofi’s Dianicline in Phase III
6.6 Acomplia (Rimonabant) has European Approval but still Waiting on FDA
6.7 Summary of Pipeline Products

7. Future Therapies

7.1 MAO-B Inhibitors – to Lessen the Shock of Withdrawal
7.2 Nicotine Metabolism Inhibitors
7.3 Vaccines to Stop Nicotine Reaching the Brain

8. The World Anti-Smoking Product Market, 2007-2012

8.1 The Worldwide Anti-Smoking Product Market, 2007-2012
8.2 NRTs Dominate the Anti-Smoking Products Market
8.3 Market Drivers
8.4 Market Restraints
8.5 Market Opportunities – Is there enough Potential for New Products

9. Key National Markets

9.1 North American Market
9.1.1 US
9.1.1.1 Smoking Prevalence in the U.S
9.1.1.2 Smoking Ban in 52 U.S States
9.1.1.3 Top Selling Products in the U.S Market
9.1.1.4 Future of the Market
9.1.1.5 Market Analysis
9.1.2 Canada
9.1.2.1 Smoking Prevalence in Canada
9.1.2.2 The Government’s Sweeping Anti-Tobacco Legislation
9.1.2.3 Top Selling Products in the Canadian Market
9.1.2.4 Future of the Market
9.1.2.5 Market Analysis
9.2 European Market
9.2.1 UK
9.2.1.1 Smoking Prevalence in the UK
9.2.1.2 New Smoking Ban Legislation to hit the UK in July
9.2.1.3 Top Selling Products in the UK Market
9.2.1.4 Future of the Market
9.2.1.5 Market Analysis
9.2.2 France
9.2.2.1 Smoking Prevalence in France
9.2.2.2 Tightening of Smoking Ban
9.2.2.3 Top Selling Products in the French Market
9.2.2.4 Future of the Market
9.2.2.5 Market Analysis
9.2.3 Sweden
9.2.3.1 Snus, a new Tobacco Perhaps?
9.2.3.2 Governement Funding Money to Strengthen Anti-Smoking Measures
9.2.3.3 Top Selling Products in the Swedish Market
9.2.3.4 Future of the Market
9.2.3.5 Market Analysis
9.2.4 Germany
9.2.4.1 Smoking Prevalence in Germany
9.2.4.2 Still a Relative Haven for Smokers
9.2.4.3 Top Selling Products in the German Market
9.2.4.4 Future of the Market
9.2.4.5 Market Analysis
9.2.5 Spain
9.2.5.1 Smoking Prevalence in Spain
9.2.5.2 New Law Protects Children & Non-Smokers
9.2.5.3 Top Selling Products in the Spanish Market
9.2.5.4 Future of the Market
9.2.5.5 Market Analysis
9.2.6 Italy
9.2.6.1 Smoking Prevalence in Italy
9.2.6.2 Third EU Country to Introduce Ban
9.2.6.3 Top Selling Products in the Italian Market
9.2.6.4 Future of the Market
9.2.6.5 Market Analysis
9.3 Asia/Australasia Market
9.3.1 Australia
9.3.1.1 Smoking Prevalence in Australia
9.3.1.2 A New $1.2 Million Anti-Smoking Campaign to be Launched
9.3.1.3 Top Selling Products in the Australian Market
9.3.1.4 Future of the Market
9.3.1.5 Market Analysis
9.3.2 Japan
9.3.2.1 Smoking Prevalence in Japan
9.3.2.2 One of the Weakest Anti-Tobacco Laws
9.3.2.3 Top Selling Products in the Japanese Market
9.3.2.4 Future of the Market
9.3.2.5 Market Analysis
9.4 Latin American Market
9.5 Summary of the National Markets

10. Company Profiles

10.1 Leading Companies
10.1.1 GSK
10.1.2 J&J
10.1.3 Pfizer
10.1.4 Novartis
10.1.5 Watson
10.1.6 Takeda

11. Conclusion

Sample Pages~Global Smoking Cessation Market Analysis & Forecasts - Preparing for the first blockbuster (Single User)|1107|Global Smoking Cessation Market Analysis & Forecasts - Preparing for the first blockbuster (Departmental)|1108|Global Smoking Cessation Market Analysis & Forecasts - Preparing for the first blockbuster (Company Wide)|1109|~2657~3296~~
Teva Pharmaceutical Industries Market Forecasts & Analysis 2007-2012~
Published by Visiongain, May 2007

In 2006, Teva Pharmaceutical Industries generated $8408m in net sales worldwide from both innovative branded and generic drugs, firmly establishing itself as a Top-20 international pharmaceutical company and leader in generics. That performance reflects rapid growth in recent years, as represented by a tripling in sales from $2519m in 2002. By 2010, total sales for Teva should reach $13.3bn. These are some of the findings from the "Teva Pharmaceutical Industries Market Forecasts 2007-2012" report, published by the business information company visiongain.~Published by Visiongain, May 2007

"Teva has a robust corporate strategy that should serve it well for years to come, driving strong growth and further innovation. Teva is therefore one of the most exciting and dynamic companies in the global pharmaceutical industry," finds visiongain report

Just some of the recent headlines surrounding Teva: In 2006, Teva Pharmaceutical Industries generated $8408m in net sales worldwide from both innovative branded and generic drugs, firmly establishing itself as a Top-20 international pharmaceutical company and leader in generics. That performance reflects rapid growth in recent years, as represented by a tripling in sales from $2519m in 2002. By 2010, total sales for Teva should reach $13.3bn. These are some of the findings from the "Teva Pharmaceutical Industries Market Forecasts 2007-2012" report, published by the business information company visiongain.

Report author Dr Gordon Low said: "With spectacular sales growth in recent quarters, Teva will raise its profile even higher in the global pharmaceutical sector. Growth will be particularly evident in branded generics and innovative products. In particular, there will be significant developments in NCE development and international business, including further launches of innovative therapeutic molecules later this decade and early in the next." Stakeholders in the industry therefore cannot afford to ignore developments in Teva.

The purpose of this visiongain report is to examine the commercial prospects for Teva Pharmaceutical Industries in the global healthcare market. Teva is already competing well there, especially in key market segments and developing geographical markets. Its profile as a leading generics and innovation-driven pharmaceutical company will continue to rise. Teva Pharmaceutical Industries 2007-2012, critically examines that company through comprehensive research, market forecasting and qualitative analyses.

Teva's leading product is Copaxone, for multiple sclerosis, which generated $1414m during 2006. Other revenues are generated from a wide portfolio of generic pharmaceutical products and another innovative drug, Azilect, a treatment for Parkinson's disease. Teva also produces and markets active pharmaceutical ingredients (APIs) for the industry worldwide.

After its acquisition of generics rival -Ivax Corporation - in a deal finalised in early 2006, Teva achieved overall leadership of the global generics market. Teva clearly has a robust corporate strategy that should serve it well for years to come, driving strong growth and further innovation. Teva is therefore one of the most exciting and dynamic companies in the global pharmaceutical industry, visiongain believes. Consequently, participants in the global market should pay close attention to developments in Teva.

Teva Pharmaceutical Industries 2007-2012 examines that company critically, through comprehensive research and analysis. Importantly, visiongain discusses Teva in the context of the wider pharmaceutical market. This market-based research involved a detailed study of commercial documents, databases, company reports and relevant news. Importantly, visiongain applied techniques such as financial forecasting, SWOT analysis and qualitative projections.

In particular, Teva Pharmaceutical Industries 2007-2012 concentrates on the following essential aspects of that company:Leading generics companies such as Teva have established a new paradigm in the generics sector: that of developing innovative drugs. Other international generics companies are in a race to catch up with Teva, the world's leader in generics and a Top-20 pharmaceutical company in its own right. Teva has already achieved success with its leading innovative product Copaxone. Visiongain predicts that Teva's sales revenues will continue to rise strongly, as it harnesses opportunities in the expanding generics market and makes further progress as a global discovery-led company.

Unique benefits to you when you order this reportTable of content:

1 Executive Summary: Teva Pharmaceutical Industries 2007-2012

2 An Introduction to Teva Pharmaceutical Industries
2.1 Teva is a Top 20 Pharmaceutical Company and Global Leader in Generics
2.2 Teva is Listed on Various Stock Exchanges, Including NASDAQ
2.3 Teva Achieved Sales of $8.4bn in 2006
2.3.1 Most of Teva's Sales are In North America
2.3.2 Most of Teva's Sales Are Generated by the Pharmaceuticals Division
2.4 Vision and Core Values in Teva
2.5 Human Pharmaceuticals Division
2.5.1 Teva Produces Generic Drugs in All Major Therapeutic Categories
2.5.2 Teva Markets and Develops Innovative Drugs for Specialised Markets
2.5.3 The Pharmaceuticals Division Contributes 90% of Teva's Revenues
2.5.4 Copaxone (glatiramer acetate)
2.5.5 Azilect (rasagiline)
2.6 Active Pharmaceutical Ingredients (API) Division
2.7 Generic Pharmaceuticals - a Comprehensive Portfolio
2.7.1 Teva USA
2.7.2 Teva Generics in Europe
2.8 Veterinary Products
2.9 Key Acquisitions by Teva
2.9.1 Acquisition of Ivax Corporation in January 2006
2.9.2 Sicor became a wholly owned subsidiary of Teva in January 2004
2.9.3 Acquisition of Novopharm
2.10 A Brief History of Teva
2.10.1 Formation of the Company at the Start of the Twentieth Century
2.10.2 Growth During the WWII and the Establishment of the State of Israel during 1940s & 50s
2.10.3 Consolidation During the 1960s & 70s - Establishment of Teva Pharmaceutical Industries Ltd
2.10.4 Further Acquisitions and Dominance During the 1980s
2.10.5 1990s: Expanding Presence Worldwide
2.11 Key Events in the History of Teva Pharmaceuticals USA

3 Teva Pharmaceutical Industries Is Responding To Challenges and Opportunities in The Market Through Ambitious Corporate Strategy
3.1 The World Pharmaceutical Market Continues to Grow, But Faces Mounting Challenges
3.2 The Continuing Success of International Pharmaceutical Companies is Dependent Upon Important Drivers and Restraints
3.3 Companies Are Gradually Changing Their Strategic Focus to Overcome Challenges in the Worldwide Market
3.4 Reduced Efficiencies in R&D Result in Concerns Over Thinning Pipelines
3.5 Driving and Restraining Forces Acting Upon Teva Pharmaceutical Industries
3.5.1 A SWOT Analysis for Teva Pharmaceutical Industries, 2007-2012
3.6 Teva Has a Focussed Strategy To Cope with Market Conditions and Opportunities
3.6.1 Teva Has Clear Strategic Objectives for the Years Ahead
3.6.2 Strategic Focus Explains Teva's Recent Growth
3.6.3 Teva is Moving Towards Higher-Value Innovative Molecules
3.7 Teva's Sales Increased Spectacularly in 2006 after Ivax Acquisition
3.7.1 Ivax Acquisition and Generics Launches Boosted Growth in 2006
3.7.2 All The Principal Geographical Regions Exhibited Strong Growth During 2006
3.7.3 Pharmaceuticals Division was a Strong Driver of Sales Growth in 2006
3.8 Teva Will Increase its Sales Substantially Between 2006 and 2012
3.8.1 From 2007-2012 Sales Will Be Driven By Strong Growth in The Pharmaceuticals Division
3.8.2 Teva Can Remain at the Forefront of the Global Generics Industry and Continue to be a Strong Niche Pharmaceutical Company
3.8.3 Cost Containment in Europe Provides Major Opportunities for Teva
3.9 Teva Reported Strong Results for the First Quarter of 2007 3.10 Generics Companies Such as Teva Must Expand Cautiously, With Valid Strategic Justification
3.10.1 Strategic Vigilance is Required
3.10.2 Generics Companies Use Acquisitions to Access New Markets - With Teva Extending Its Geographic and Technological Reach in That Manner
3.10.3 Teva Has Expanded for Justifiable Strategic Reasons
3.10.4 2007 Will Provide Major Opportunities for Teva, As Will the Period 2010-2012
3.10.5 Teva Recently Expanded Its Manufacturing Facilities in Jerusalem
3.11 Teva Has Benefited from a Vigorous Acquisitions Strategy
3.11.1 Teva Took Advantage of The Hatch-Waxman Act of 1984
3.11.2 Important Acquisitions in Recent Years - Culminating in the Incorporation of Ivax - Have Benefited Teva Immensely
3.11.3 Teva-Ivax Marked the Second Major Generics Acquisition in Recent Times
3.11.4 Differentiation in the Market is Vital to the Continuing Success of Teva - In That Way Teva Can Withstand Downward Pressure On Prices in Conventional Generic Drugs
3.11.5 Incorporation of Ivax in January 2006 Gave Teva Pre-Eminence in the Expanding Global Generics Market
3.11.6 Acquisition of acquisition of Dorom Srl in 2004
3.11.7 Teva and US Company Sicor Signed a Definitive Agreement in 2004
3.11.8 Acquisition of Bayer's and Merck & Co's French Generics Units in 2002
3.11.9 2000 Was Marked by Acquisitions of Novopharm and Human Serum & Pharma 3.11.10 Copley Pharmaceutical Institute for Drug Research Acquired in 1999
3.11.11 The 1990s Saw Other Acquisitions by Teva
3.12 Teva Makes Good Use of International Subsidiaries
3.12.1 Most of Teva's Sales Revenues Are Generated in the US
3.12.2 Europe Also Achieved a Significant Contribution to Revenue
3.12.3 Teva Has Dominance in The US Generics Market After Incorporating Ivax
3.12.4 Significant Global Expansion Since Late 1990s
3.13 In Common With Other Generics Companies, Teva Faces Litigation Over Patent-Related Issues
3.13.1 Paragraph IV Certification
3.13.2 Bayer Filed Lawsuit Against Teva Over Avelox
3.13.3 Teva Provided Update On Litigation Over Generic Celebrex
3.13.4 Agreement With Biovail And Anchen Regarding Generic Wellbutrin XL
3.13.5 Settlement Over Cephalon's Provigil
3.13.6 Exclusivity for Generic Zocor Not Attained But Strong Revenues for Teva's Generic Expected
3.13.7 Teva in Litigation with Abbott
3.13.8 Teva Will Continue to Supply Generic Oxycodone Throughout 2007
3.13.9 Teva Filed Patent Infringement Complaints Regarding Sertraline Hydrochloride 3.13.10 Agreement With Pfizer Regarding Idarubicin, Azithromycin, And Epirubicin
3.14 Teva: Collaborations and Licensing
3.14.1 Abitren/Diclofenac Q
3.14.2 Azilect
3.14.3 Budeprion SR
3.14.4 Copaxone
3.14.5 Diltiazem
3.14.6 Nifedipine ER/Nifedipine Teva
3.14.7 Previfem/Tri-Previfem
3.14.8 Purinethol
3.14.9 Purinethol
3.14.10 Quinapril Teva
3.14.11 Verapamil
3.14.12 Zavesca
3.15 ProNeuron Biotechnologies Filed to Annul License Agreement with Teva Over Clinical Trials

4 Pharmaceuticals Division
4.1 The Pharmaceuticals Division Will Yield Strong Growth, Strongly Driving Overall Corporate Revenues
4.1.1 Teva Benefited from an Ambitious Strategy of Acquisition
4.1.2 Teva Had Over 150 Products Awaiting FDA Approval at the End of 2006
4.1.3 Promising First Quarter Results for 2007
4.2 Copaxone - Teva's First Innovative Drug to Receive FDA Approval
4.2.1 Steady Revenue Increase Expected for Teva's Flagship Product
4.2.2 Copaxone Faces Present and Future Competitive Challenges in the Market
4.2.3 Copaxone Was Originally Licensed from the Weizmann Institute of Science
4.2.4 Copaxone is the Subject of Promising Clinical Studies
4.2.5 Lifecycle Management of Copaxone: Teva Makes Good Use of Collaborations
4.3 Azilect - Teva's Recently Launched Innovative Product
4.3.1 Azilect is Currently In a Period of High Early Growth
4.3.2 Azilect is a Potent Agent for Early and Advanced Parkinson's Disease
4.3.3 Azilect Benefits from Convenient Dosing
4.3.4 Azilect is Co-Marketed in Europe by Lundbeck and Teva
4.3.5 Co-Development of Azilect with Eisai
4.3.6 Phase IV Post-Marketing Study to Investigate Risk of Melanoma
4.3.7 Azilect May Have Potential in the Early Treatment of Parkinson's
4.3.8 Competition for Azilect
4.3.9 Azilect Has Performed Well in Clinical Studies
4.4 Teva Has a Diverse Generics Portfolio
4.4.1 Revenues from Generics Spread Over Many Products
4.4.2 Teva Receives First US Approval For Generic Uniretic Tablets
4.4.3 Teva Receives Approval For Generic Dostinex Tablets
4.4.4 Teva Announced Approval of Alprazolam ER Tablets
4.4.5 Teva Announced Its Launch of Generic Wellbutrin XL Tablets Through Agreement With Anchen And IMPAX
4.4.6 Teva Announced Tentative Approval Of Sumatriptan Succinate Tablets
4.4.7 Teva Receives Approval for Generic Focalin Tablets
4.4.8 Teva Announced Agreement with Pfizer Regarding Idarubicin, Azithromycin, And Epirubicin
4.4.9 Launch of Generic Zoloft by Teva
4.4.10 Final Approval of Venlafaxine HCL Tablets
4.4.11 Final Approval of Meloxicam Tablets
4.4.12 Tentative Approval of Generic Lotrel
4.4.13 Approval of Generic Zocor
4.4.14 Teva Received First FDA Approval for Generic Proscar Tablets
4.4.15 Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets
4.4.16 Tentative Approval for Generic Cozaar Tablets
4.4.17 Tentative Approval of Simvastatin Tablets
4.4.18 Approval of Generic Lexapro Tablets
4.5 The Integration of Ivax's Operations Greatly Increased Teva's Strengths in Respiratory Drugs
4.6 Acquisition of Ivax is a Major Coup for Teva
4.6.1 Ivax Acquisition Brought Expertise in Respiratory Field in Particular
4.6.2 As a Condition of the Acquisition, Teva and Ivax Had To Divest Some Products in US Market
4.7 Teva is Active in OTC Products
4.7.1 OTC Products Part of Pharmaceuticals Division
4.7.2 Out-Licensing to Perrigo
4.7.3 Zirtek (cetirizine) Approval Delayed

5 Active Pharmaceutical Ingredients
5.1 Active Pharmaceutical Ingredients Division Will Show Steady Growth, Playing a Supporting Role
5.2 Teva's API Division is a Major Supplier to the Global Pharmaceutical Industry
5.3 Active Pharmaceutical Ingredients Division Will Benefit from Expanding Global Pharmaceutical Market
5.4 Acquisition of Sicor Brought Valuable Expertise and Capacity in the Production of APIs
5.5 Teva Prides itself on its Technological Capabilities in API Production
5.6 Active Pharmaceutical Ingredients Achieved Similar Growth in Q1 2007 as in Q1 of 2006
5.7 Ivax Acquisition Has Brought Another 30 APIs to Teva's Portfolio
5.8 Teva's Expansion into the Japanese API Market in 2006
5.9 Teva Produces APIs Internationally
5.10 Visiongain Concludes that Teva Will Remain at the Forefront of API Supply and Custom Pharmaceutical Manufacturing Throughout the Forecast Period 2007-2012

6 Pipeline Developments in Teva
6.1 Teva is Conducting R&D in Important Therapeutic Areas
6.2 Teva's Investment in R&D Has Been Rising in Recent Years
6.3 As a Leading Generic Producer Teva Has Progressed into Innovative Research & Development
6.4 Teva Has a Very Strong Generics Pipeline in Addition to Innovative Developments
6.4.1 R&D Focussed on Multiple Sclerosis, Autoimmune Diseases, Neurology and Oncology
6.4.2 Teva R&D is Concentrated in Three Divisions
6.4.3 Generic and Innovative Pipelines Are Strong - Ivax Acquisition Paying Off
6.5 Antineoplastics/Immunomodulating Agents
6.5.1 Stemex Cell Therapy
6.5.2 HMN 214
6.5.3 EDRATIDE (TV 4710)
6.5.4 SAIK-MS
6.5.5 LMB 9
6.5.6 Cervene (TP 38)
6.6 Central Nervous System Agents
6.6.1 Citicoline (IP 302)
6.6.2 Cladribine (NSC 105014F)
6.6.3 Fampridine-SR
6.6.4 Ladostigil
6.6.5 Valrocemide
6.7 Genitourinary System/Sex Hormones
6.8 Respiratory System Agents
6.8.1 Respicort
6.8.2 Other Agents in Development
6.9 Licensing Deal With Vaccinex for Monoclonal Antibody 6.10 Teva Collaborates on Protalix's recombinant plant cell expression technology
6.11 Teva And Procognia (Israel) Ltd. Sign an Exclusive Collaboration Agreement for the Development of Biopharmaceuticals

7 Conclusions7.1 Teva is a Top-20 Pharmaceutical Company with a Diverse Portfolio of Generic and Innovative Products
7.2 Ivax Acquisition and Generics Launches Boosted Growth in 2006
7.3 Sales in Teva are Dominated by the Pharmaceuticals Division
7.4 From 2007-2012 Sales Will Be Driven By Strong Growth in The Pharmaceuticals Division
7.5 Generic and Innovative Pipelines Are Strong
7.6 Teva Can Remain at the Forefront of the Global Generics Industry and Continue to be a Strong Niche Pharmaceutical Company With Impressive Sales Worldwide

Appendices
Appendix 1: Major Drugs Facing Patent Expiry in the US, 2004-2009
Appendix 2: About Visiongain
Appendix 3: Visiongain Report Evaluation Form

List of Tables
Table 2.1 Top 20 Global Pharmaceutical Companies, 2005
Table 2.2 Teva Net Sales and Income, 2002-2006
Table 2.3 Teva Subsidiaries, 2006
Table 2.4 Sales ($m) by Geographical Area, 2004-2006
Table 2.5 Sales ($m) by Business Division, 2004-2006
Table 2.6 Major Events in Teva USA's History
Table 3.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 2000-2006
Table 3.2 A SWOT Chart for Teva, 2007-2012
Table 3.3 Teva - Main Financials* ($m), 2005 and 2006
Table 3.4 Sales ($m) by Geographical Region, 2006
Table 3.5 Sales ($m) by Division, 2006
Table 3.6 Teva Sales ($m) by Division and Total Sales, 2006-2012
Table 3.7 Contribution (%) of Total Sales by Division, 2006 and 2012
Table 3.8 Teva Pharmaceutical Sales by Geographical Region and Leading National Markets, June 2005 to June 2006
Table 4.1 Pharmaceuticals Divisional Sales ($m), 2006-2012
Table 4.2 Copaxone and Azilect Sales ($m), 2006-2012
Table 4.3 Copaxone and Azilect Contribution to Sales (%), 2006-2012
Table 4.4 Copaxone Sales ($m), 2006-2012
Table 4.5 Sales ($m), 2006-2012
Table 4.6 Principal Therapeutic Products Manufactured by Teva, 2006
Table 4.7 Teva Pharmaceuticals: Top Five Therapeutic Classes, 2005-2006
Table 4.8 Pharmaceuticals: Leading International Products, 2005-2006
Table 5.1 Active Pharmaceutical Ingredients Divisional Sales ($m), 2006-2012
Table 6.1 R&D Investment by Teva, 2002-2006
Table 6.2 Antineoplastics/Immunomodulating Agents Pipeline
Table 6.3 Central Nervous System Agents
Table 6.4 Genitourinary System/Sex Hormones
Table 6.5 Respiratory System Agents
Table 6.6 Other Agents in Development
Table 7.1 Teva Sales ($m) by Division and Total Sales, 2006-2012

List of Figures
Figure 2.1 Teva Net Sales, 2002-2006
Figure 2.2 Teva Net Income, 2002-2006
Figure 2.3 Sales ($m) by Geographical Area, 2004-2006
Figure 2.4 Sales ($m) by Business Division, 2004-2006
Figure 2.5 Teva Employee Numbers, 2005 & 2006
Figure 3.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 2000-2006
Figure 3.2 Teva - Main Financials* ($m), 2005 and 2006
Figure 3.3 Sales ($m) by Geographical Region, 2006
Figure 3.4 Contribution (%) of Sales by Geographical Region, 2006
Figure 3.5 Sales ($m) by Division, 2006 Figure 3.6 Contribution (%) of Sales by Division, 2006
Figure 3.7 Teva Corporate Sales ($m), 2006-2012
Figure 3.8 Teva Sales ($m) by Division and Total Sales, 2006-2012
Figure 3.9 Sales ($m) by Division and Total Sales ($m), 2006 & 2012
Figure 3.10 Contribution (%) of Total Sales by Division, 2012
Figure 3.11 Teva Pharmaceutical Sales by Geographical Region and Leading Countries, June 2005 to June 2006
Figure 4.1 Pharmaceutical Division Sales ($m), 2006-2012
Figure 4.2 Copaxone and Azilect Sales ($m), 2006-2012
Figure 4.3 Copaxone and Azilect: Relative Contributions (%) to Teva Sales, 2006 and 2012
Figure 4.4 Copaxone Sales ($m), 2006-2012
Figure 4.5 Azilect Revenues ($m), 2006-2012
Figure 5.1 Active Pharmaceutical Ingredients Division Sales ($m), 2006-2012
Figure 6.1 R&D Investment by Teva, 2002-2006
Figure 7.1 Teva - Main Financials* ($m), 2005 and 2006
Figure 7.2 Teva Sales ($m) by Division and Total Sales, 2006-2012

Sample Pages~Teva Pharmaceutical Industries Market Forecasts & Analysis 2007-2012 (Single User License)|1061|Teva Pharmaceutical Industries Market Forecasts & Analysis 2007-2012 (Departmental License)|1062|Teva Pharmaceutical Industries Market Forecasts & Analysis 2007-2012 (Company Wide License)|1063|~2657~3249~~
Gastrointestinal Disorders Market Intelligence to 2012~
Published by Visiongain, May 2007

Gastrointestinal (GI) disorders are set to affect over 250 million people in the seven largest pharma markets, by 2012. As generations of people become more obese and consume increasingly poor diets then so too will the number of people suffering from these disorders rise.~Gastrointestinal (GI) disorders are set to affect over 250 million people in the seven largest pharma markets, by 2012. As generations of people become more obese and consume increasingly poor diets then so too will the number of people suffering from these disorders rise.

At present, the pharmaceutical prescription market to treat GI disorders market is valued at just over $20 billion, reflecting that it is one of the largest and most important therapeutic areas in the pharmaceutical industry. Visiongain has just produced a business intelligence report, Gastrointestinal Disorders 2007-2012, which addresses the state of this market, and assesses how it will develop in the future. Are you involved in this market area? Will the future of this market affect your business?

AstraZeneca's Nexium is currently the most successful GI drug available in the market, based on sales revenues totaling more than $6 billion. What is the future for Nexium? How will its impact shape the GI market? Will other GI drugs reach blockbuster status? If so, which ones? Find out in this vital report.

Another example of change in the GI market is the withdrawal of Novartis's from the US market, due to safety and efficacy issues. What effects will this have on the other GI drugs? How will this affect the overall GI market? What does the future hold for Novartis and Zelnorm? These are all crucial questions that need answers, which can be found by buying this visiongain report.

Visiongain's World Gastrointestinal Disorders report includes three major classes of product which visiongain believes will extensively occupy the GI market. These are:

Proton Pump Inhibitors (PPIs)
Histamine H2 Receptor Antagonists
Other Leading GI agents
Which new drugs will be marketed? Which drugs will have the most impact on the market? Most importantly, what are the future prospects of the GI market?

The following crucial aspects of the GI market are discussed:

The current world GI market
SWOT Analysis of the GI market
Revenue Forecasts for all the drugs analysed 2007-2012 Market Activity Geographical breakdown of GI market Potential treatment population forecasted to 2012 for major leading global markets Discussion on comparative pricing of the major GI drugs Analysing the major generic/substitute products Detailed information on pipeline products Discussion on possible future strategies in GI market

Why You Must Buy This Report:

This 180+ paged report features 47 figures which includes graphs and charts, 28 tables, insight, and include the latest developments in the gastrointestinal market with up-to-date analysis.

This report will give you the understanding you require to gain that competitive edge in the GI market. This large revenue producing therapeutic area is in the top ten of the largest earning revenues in the pharma industry. Therefore, it is vital that the latest gastrointestinal report is brought without fail.

The revenue forecasts generated in this report are highly accurate and are determined by the market and its future prospects in terms of patent protection, generic competition, life-cycle management, licensing agreements and market activity. The forecast runs up to 2012. Therefore it gives your company sound understanding of how GI drug will behave up until that time.

Key questions that this report answers:

What are the most influential GI disorders and their impacts?
Which drugs are dominating their classes in the GI market?
What is the revenue potential in 2012 for these drugs?
What market activity is occurring? (What are pharma companies doing?) What is the potential population treatment in the major global markets up to 2012?
Which is the status of the GI pipeline?

Unique benefits to you when you order this report:

Executive Summary: Gastrointestinal Treatments Constitute A Considerable Increase in the Market

Chapter 2: Introduction to Gastrointestinal Disorders
2.1 Gl Conditions are Widespread
2.1.1 Gl Disorders have a Considerable Impact on Society
2.1.2 GI Drugs Represented in the Top 100 Best Selling Prescription Drugs
2.2 Gastroesophageal Reflux Disease
2.2.1 What is Gastroesophageal Reflux Disease (GERD)?
2.2.2 Causes of GERD
2.2.3 Symptoms of the Condition
2.2.4 Identifying The GERD
2.2.5 Incidence of GERD
2.2.6 Economic Impact of GERD
2.3 Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
2.3.1 What is Crohn's Disease?
2.3.2 Causes of Crohn's Disease
2.3.3 Symptoms of Crohn's Disease
2.3.4 Identifying the Condition
2.3.5 What is Ulcerative Colitis?
2.3.6 Causes of Ulcerative Colitis
2.3.7 Symptoms of Ulcerative Colitis
2.3.8 Identifying Ulcerative Colitis
2.3.9 Worldwide Occurrence of IBD - Crohn's Disease Is Increasing Throughout the W